Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC). Doebele, R., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D., Neal, J. W., Zhang, S., Reichmann, W., Kerstein, D., Li, S., Janne, P. A. AMER SOC CLINICAL ONCOLOGY. 2018
View details for DOI 10.1200/JCO.2018.36.15_suppl.9015
View details for Web of Science ID 000442916003189